| abstract |
The present invention relates to a novel imidazolinone derivative of the general formula (I) having a positive allosteric modulator for metabotropic glutamate receptor subtype 2 (mGlu2 receptor), or a pharmaceutical thereof Permissible salt can be used as schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, anxiety disorder, depression, AD/HD (lack of attention/hyperactivity disorder), drug dependence, paralysis, It is useful for the prevention or treatment of diseases such as shivering and sleep disorders. |